2,925 reports of this reaction
2.3% of all OXALIPLATIN reports
#9 most reported adverse reaction
DYSPNOEA is the #9 most commonly reported adverse reaction for OXALIPLATIN, manufactured by Accord Healthcare Inc.. There are 2,925 FDA adverse event reports linking OXALIPLATIN to DYSPNOEA. This represents approximately 2.3% of all 127,128 adverse event reports for this drug.
OXALIPLATIN has an overall safety score of 92 out of 100. Patients taking OXALIPLATIN who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for OXALIPLATIN, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for OXALIPLATIN:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 2,925 FDA reports for OXALIPLATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.3% of all adverse event reports for OXALIPLATIN, making it a notable side effect.
If you experience dyspnoea while taking OXALIPLATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.